NIRSE-GAL updates

Publications

Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

Analysis of the effectiveness and impact of the monoclonal antibody Nirsevimab in relation to admissions for acute lower respiratory tract infection caused by Respiratory Syncytial Virus.

January 21, 2025

Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

Media: The Lancet Infectious Diseases

Full 2023–2024 season results of universal prophylaxis with Nirsevimab in Galicia, Spain: the NIRSE-GAL study. With coverage exceeding 90%, immunization significantly reduced RSV-related hospitalizations, achieving 70.7% effectiveness for general hospitalizations and 80.3% for cases requiring oxygen support. The results highlight the positive impact of universal strategies in RSV prevention and support their global adoption.

December 13, 2024

Nirse-Gal Study protocol (Human Vaccine & Immunotherapeutics)

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Galicia (Spain) pioneered in implementing nirsevimab as a universal prophylactic measure against RSV. To evaluate nNrsevimab effectiveness against RSV and its severe forms and to assess the impact of nirsevimab implementation, the NIRSE-GAL study (www.nirsegal.es) was established in collaboration with the Galician Directorate of Public Health of the Xunta de Galicia. Here, we present the study protocol s considered to carry on this project.

October 29, 2024

The Lancet Infectious Diseases – Nirse-Gal Study Paper

Effectiveness and impact of universal prophylaxis with Nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.

Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital).

May 1, 2024

The Journal of Infectious Diseases

Preparing Europe for Introduction of Immunization Against RSV: Bridging the Evidence and Policy Gap.

On the cover: RSV Immunization: From Bench to Arms. The first picture is from the immunization campaign in Galicia, Spain this winter, where they successfully immunized all their children under one year of age with spectacular results. Credit: Prof Federico Martinon-Torres and Mr Carlos Bermello. The second picture is of Prof Barney Graham, who led the discovery of the structure of the F protein that revolutionized the field of RSV vaccines. He is holding a 3D model of the structure of the F protein while getting immunized at Walgreens community pharmacy last autumn. Credit: Dr. Cynthia Turner-Graham.

March 19, 2024

Eurosurveillance

Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C.

Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.

March 19, 2024